OWP PHARMACEUTICALS Press Releases - EIN Presswire - Press Release Distribution Service

Published on January 12, 2026 - 14:13 GMT

OWP Pharmaceuticals Announces Commercial Product Availability of SUBVENITE® (lamotrigine) Oral Suspension in U.S. Market

LISLE, IL, UNITED STATES, January 12, 2026 /⁨EINPresswire.com⁩/ -- OWP Pharmaceuticals today announced commercial product availability of SUBVENITE® (lamotrigine) oral suspension in the United States. The U.S. Food and Drug Administration (FDA) approved …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on September 17, 2025 - 22:07 GMT

OWP Pharmaceuticals Announces FDA Approval of SUBVENITE® Oral Suspension

The First and Only Lamotrigine Oral Suspension in the U.S. LISLE, IL, UNITED STATES, September 17, 2025 /⁨EINPresswire.com⁩/ -- OWP Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved SUBVENITE® Oral Suspension …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on May 20, 2024 - 15:17 GMT

OWP Pharmaceuticals Announces FDA Filing Acceptance for New Drug Application of SUBVENITE® (lamotrigine) Oral Suspension

NAPERVILLE, ILLINOIS, UNITED STATES, May 20, 2024 /⁨EINPresswire.com⁩/ -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on August 1, 2023 - 19:48 GMT

OWP Pharmaceuticals Announces IND Authorization for First Oral Liquid Formulation of Trazodone for Treatment of MDD

NAPERVILLE, ILLINOIS, UNITED STATES, August 1, 2023 /⁨EINPresswire.com⁩/ -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid …

Distribution channels: Healthcare & Pharmaceuticals Industry ...